ARS Pharmaceuticals (SPRY) Receivables (2023 - 2026)

ARS Pharmaceuticals (SPRY) has 4 years of Receivables data on file, last reported at $28.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 179.19% year-over-year to $28.7 million; the trailing twelve-month figure through Mar 2026 stood at $28.7 million (up 179.19% YoY), and the FY2025 full-year result was $25.3 million, up 169.45% from the prior year.
• Receivables rose to $28.7 million in Q1 2026, from $25.3 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $40.7 million in Q3 2025 to a low of $652000.0 in Q4 2023.
• A 4-year average of $17.9 million and a median of $17.8 million in 2025 frame the typical range for Receivables.
• Peak annual rise in Receivables reached 4394.48% in 2025, while the deepest fall reached 169.45% in 2025.
• Tracing SPRY's Receivables over 4 years: stood at $652000.0 in 2023, then surged by 1342.79% to $9.4 million in 2024, then soared by 169.45% to $25.3 million in 2025, then increased by 13.08% to $28.7 million in 2026.
• Business Quant data shows SPRY's Receivables at $28.7 million in Q1 2026, $25.3 million in Q4 2025, and $40.7 million in Q3 2025.